397 related articles for article (PubMed ID: 29262744)
1. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
Scipione CA; Koschinsky ML; Boffa MB
Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
[TBL] [Abstract][Full Text] [Related]
2. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung MY; Tsimikas S
Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
[TBL] [Abstract][Full Text] [Related]
3. New Frontiers in Lp(a)-Targeted Therapies.
Borrelli MJ; Youssef A; Boffa MB; Koschinsky ML
Trends Pharmacol Sci; 2019 Mar; 40(3):212-225. PubMed ID: 30732864
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.
Guddeti RR; Patil S; Ahmed A; Sharma A; Aboeata A; Lavie CJ; Alla VM
Prog Cardiovasc Dis; 2020; 63(4):496-502. PubMed ID: 32526213
[TBL] [Abstract][Full Text] [Related]
5. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.
Yeang C; Wilkinson MJ; Tsimikas S
Curr Opin Cardiol; 2016 Jul; 31(4):440-50. PubMed ID: 27205885
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement.
Ma GS; Wilkinson MJ; Reeves RR; Yeang C; DeMaria AN; Cotter B; Patel M; Mahmud E; Tsimikas S
Angiology; 2019 Apr; 70(4):332-336. PubMed ID: 30700108
[TBL] [Abstract][Full Text] [Related]
8. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
[TBL] [Abstract][Full Text] [Related]
9. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.
Capoulade R; Chan KL; Yeang C; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Mahmut A; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
J Am Coll Cardiol; 2015 Sep; 66(11):1236-1246. PubMed ID: 26361154
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
Nsaibia MJ; Mahmut A; Boulanger MC; Arsenault BJ; Bouchareb R; Simard S; Witztum JL; Clavel MA; Pibarot P; Bossé Y; Tsimikas S; Mathieu P
J Intern Med; 2016 Nov; 280(5):509-517. PubMed ID: 27237700
[TBL] [Abstract][Full Text] [Related]
11. The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting.
Wilkinson MJ; Ma GS; Yeang C; Ang L; Strachan M; DeMaria AN; Tsimikas S; Cotter B
Angiology; 2017 Oct; 68(9):795-798. PubMed ID: 28068801
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
Vuorio A; Watts GF; Kovanen PT
Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
[TBL] [Abstract][Full Text] [Related]
13. Calcific Aortic Valve Stenosis and Atherosclerotic Calcification.
de Oliveira Sá MPB; Cavalcanti LRP; Perazzo ÁM; Gomes RAF; Clavel MA; Pibarot P; Biondi-Zoccai G; Zhigalov K; Weymann A; Ruhparwar A; Lima RC
Curr Atheroscler Rep; 2020 Jan; 22(2):2. PubMed ID: 31912380
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.
Zheng KH; Tsimikas S; Pawade T; Kroon J; Jenkins WSA; Doris MK; White AC; Timmers NKLM; Hjortnaes J; Rogers MA; Aikawa E; Arsenault BJ; Witztum JL; Newby DE; Koschinsky ML; Fayad ZA; Stroes ESG; Boekholdt SM; Dweck MR
J Am Coll Cardiol; 2019 May; 73(17):2150-2162. PubMed ID: 31047003
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia.
Vongpromek R; Bos S; Ten Kate GJ; Yahya R; Verhoeven AJ; de Feyter PJ; Kronenberg F; Roeters van Lennep JE; Sijbrands EJ; Mulder MT
J Intern Med; 2015 Aug; 278(2):166-73. PubMed ID: 25487646
[TBL] [Abstract][Full Text] [Related]
16. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
Boffa MB; Koschinsky ML
Curr Opin Lipidol; 2018 Jun; 29(3):259-267. PubMed ID: 29528858
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective.
Arsenault BJ; Kamstrup PR
Atherosclerosis; 2022 May; 349():7-16. PubMed ID: 35606078
[TBL] [Abstract][Full Text] [Related]
18. The re-emergence of lipoprotein(a) in a broader clinical arena.
Tsimikas S
Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis.
Cao J; Steffen BT; Budoff M; Post WS; Thanassoulis G; Kestenbaum B; McConnell JP; Warnick R; Guan W; Tsai MY
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):1003-9. PubMed ID: 26941019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
